Denali Therapeutics Inc.

Denali Therapeutics Inc. is a biotechnology company headquartered in South San Francisco, California, dedicated to discovering, developing, and delivering therapeutics to defeat neurodegenerative diseases and lysosomal storage disorders. The company's core mission is to overcome the significant challenge of delivering medicines across the blood-brain barrier (BBB) to effectively treat these complex conditions.

Central to Denali's approach is its proprietary Transport Vehicle™ (TV) platform, which includes Enzyme Transport Vehicle (ETV), Oligonucleotide Transport Vehicle (OTV), and Antibody Transport Vehicle (ATV) technologies. This platform is engineered to transport large therapeutic molecules, such as enzymes, oligonucleotides, and antibodies, across the blood-brain barrier to reach target tissues in the brain. The company's pipeline spans a broad range of investigational therapies for conditions including Alzheimer's disease, Parkinson's disease, Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), Hunter syndrome (MPS II), Sanfilippo syndrome type A (MPS IIIA), and Pompe disease. Key programs include AVLAYAH™ (tividenofusp alfa-eknm) for Hunter syndrome, DNL126 for Sanfilippo syndrome type A, DNL593 for FTD-GRN, and BIIB122/DNL151 for Parkinson's disease.

Denali Therapeutics is led by co-founder, President, and CEO Ryan Watts, Ph.D. A significant recent milestone for the company was the U.S. FDA approval of AVLAYAH™ (tividenofusp alfa-eknm) for the treatment of Hunter syndrome (MPS II) on March 25, 2026, marking its first commercial launch. The company also recently regained full rights to its investigational therapy DNL593 for FTD-GRN on April 3, 2026, following the termination of a collaboration with Takeda, and plans to continue its clinical development. Denali operates as a publicly traded company on the NASDAQ stock exchange under the ticker symbol DNLI.